Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

Core Insights - Harmony Biosciences Holdings, Inc. reported earnings of $239.5 million for Q3 2025, marking a 29% year-over-year revenue growth for WAKIX® [1] - The revenue growth was driven by an increase of approximately 500 in the average number of patients for the quarter, indicating a strong trajectory towards blockbuster status for WAKIX in the treatment of narcolepsy [1] - The company has achieved four consecutive years of revenue growth and profitability, showcasing its strong market position and operational success [1]